Table 1 Patient and reporter characteristics of the adverse event reports from 2011Q1-2023 Q4.
From: Signal detection of immune thrombocytopenia associated with immune checkpoint inhibitors
Characteristic | Reports of acquired immune thrombocytopenia (n = 404) |
|---|---|
Age | |
≥86 | 8 (2.0%) |
65 ~ 85 | 206 (51.0%) |
18 ~ 64 | 101 (25.0%) |
Missing | 89 (22.0%) |
Weight | |
>100 kg | 8 (2.0%) |
50 ~ 100 kg | 108 (26.7%) |
<50 kg | 28 (6.9%) |
Missing | 260 (64.4%) |
Sex | |
Male | 243 (60.1%) |
Female | 114 (28.2%) |
Missing | 47 (11.6%) |
Reporter country | |
Japan | 182 (45.0%) |
United States | 85 (21.0%) |
France | 30 (7.4%) |
Germany | 24 (5.9%) |
Canada | 9 (2.2%) |
Others | 74 (18.32%) |
Reporter’s occupation | |
Physician | 33 (8.2%) |
Health professional | 66 (16.3%) |
Consumer | 43 (10.6%) |
Medical doctor | 210 (52.0%) |
Other health professional | 52 (12.9%) |
Outcome* | |
Other serious outcome | 346 (47.0%) |
Hospitalization | 212 (28.8%) |
Death | 68 (9.2%) |
Life-threatening condition | 79 (10.7%) |
Disability | 11 (1.5%) |
Missing | 20 (2.7%) |
Report date | |
2011 | 0 (0%) |
2012 | 2 (0.5%) |
2013 | 4 (1.0%) |
2014 | 2 (0.5%) |
2015 | 4 (1.0%) |
2016 | 13 (3.2%) |
2017 | 38 (9.4%) |
2018 | 43 (10.6%) |
2019 | 69 (17.1%) |
2020 | 47 (11.6%) |
2021 | 76 (18.8%) |
2022 | 54 (13.4%) |
2023 | 52 (12.9%) |
